Eur Rev Med Pharmacol Sci 2022; 26 (14): 5255-5263

DOI: 10.26355/eurrev_202207_29316

The SARS-CoV-2 rS1-E-PLGA nanovaccine and evaluation of its immune effect in BALB/c mice

J. Huang, Y. Ding, J. Yao, K. Peng, K. Deng, M. Zhang, Y. Zhang, J. Zuo

The Laboratory of Translational Medicine, Nanhua Hospital Affiliated to University of South China, The Third Affiliated Hospital of University of South China, Institute of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, Hunan, P.R. China. 632138414@qq.com


OBJECTIVE: Vaccination is an important method for preventing COVID-19 infection. However, certain vaccines do not meet the current needs. To improve the vaccine effect, discard ineffective antigens, and focus on high-quality antigenic clusters, S1-E bivalent antigens were designed.

MATERIALS AND METHODS: Vaccine delivery is performed using poly (lactic-co-glycolic acid) (PLGA). Here, the recombinant S1-E (rS1-E) was covered on PLGA and injected intramuscularly into mice. In total, 48 BALB/c mice were randomly divided into six groups with 8 mice in each group. The mice received intramuscular injections. Prior to vaccination, the hydrophobicity of the rS1-E and the antigenic site of the E protein were both analysed. The morphology, zeta potential, and particle size distribution of rS1-E-PLGA were examined. Anti-S1 and anti-E antibodies were detected in mouse serum by ELISA. Neutralising an-tibodies were detected by co-incubating the pseudovirus with the obtained serum. IL-2 and TNF-α levels were also measured.

RESULTS: The designed recombinant S1-E protein was successfully coated on PLGA nanoparticles. rS1-E-PLGA nanovaccine has suitable size, shape, good stability, sustained release and other characteristics. Importantly, mice were stimulated with rS1-E-PLGA nanovaccines to produce high-titre antibodies and a good cellular immune response.

CONCLUSIONS: Our results indicate that rS1-E-PLGA nanovaccine may provide a good protective effect, and the vaccine should be further investigated in human clinical trials for use in vaccination or as a booster.

Free PDF Download

To cite this article

J. Huang, Y. Ding, J. Yao, K. Peng, K. Deng, M. Zhang, Y. Zhang, J. Zuo
The SARS-CoV-2 rS1-E-PLGA nanovaccine and evaluation of its immune effect in BALB/c mice

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 14
Pages: 5255-5263
DOI: 10.26355/eurrev_202207_29316